?Dexamethasone Sodium Phosphate (CAS 2392-39-4)?
? ?Product Overview?
Dexamethasone Sodium Phosphate, a synthetic glucocorticoid with the molecular formula ?C??H??FNa?O?P?, is a potent anti-inflammatory and immunosuppressive agent widely used in clinical and research settings. It effectively manages conditions such as severe inflammation, autoimmune disorders, and adrenal insufficiency, while serving as a critical intermediate in pharmaceutical development.

? ?Key Advantages?
?? ?Pharmaceutical-Grade Purity?: ≥99% verified by HPLC, ensuring reliability in formulations.
?? ?Thermal Stability?: Melting point ?233–235°C?, ideal for stable storage and transport.
?? ?Regulatory Compliance?: Meets ?USP42? and ?EP9? pharmacopeial standards for global acceptance.

? ?Applications?

• ?Clinical Therapy?: Treatment of asthma, rheumatoid arthritis, and allergic reactions.

• ?Biomedical Research?: Mechanistic studies on glucocorticoid receptor pathways.

• ?Drug Formulation?: Key intermediate for injectable solutions and reference standards.

? ?Quality Assurance?
Rigorously tested via ?HPLC?, ?FTIR?, and ?mass spectrometry?, with batch-specific Certificates of Analysis (COAs). Stability studies comply with ICH guidelines for long-term storage.

? ?Market Insights?
The global glucocorticoid market is projected to grow at ?4.8% CAGR (2025–2030)?, driven by rising demand for advanced anti-inflammatory therapies and targeted drug delivery systems. Dexamethasone Sodium Phosphate remains pivotal in both therapeutic and R&D applications due to its proven efficacy and safety profile.